A randomized, open label, parallel-group, international, multicenter study evaluating persistency of response to omalizumab during 32 weeks treatment given as add on to optimized asthma therapy in adult and adolescent patients with severe persistent allergic asthma, who remain inadequately controlled despite GINA [Global Initiative for Asthma] (2004) step 4 therapy

Trial Profile

A randomized, open label, parallel-group, international, multicenter study evaluating persistency of response to omalizumab during 32 weeks treatment given as add on to optimized asthma therapy in adult and adolescent patients with severe persistent allergic asthma, who remain inadequately controlled despite GINA [Global Initiative for Asthma] (2004) step 4 therapy

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Allergic asthma
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 27 Jul 2011 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.
    • 22 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 May 2010 Quality-of-life and resource use analyses presented at the 106th International Conference of the American Thoracic Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top